Axsome Therapeutics Eyes $2 Billion Market Following FDA Approval for Alzheimer's Agitation Treatment

Axsome Therapeutics (NASDAQ: AXSM) is positioning itself for substantial growth after receiving U.S. Food and Drug Administration (FDA) approval for Auvelity to treat agitation associated with dementia due to Alzheimer's disease. The approval triggered a 22.9% increase in share price during April as investors reacted to the expanded utility of the drug. Auvelity has already demonstrated strong commercial momentum, with sales increasing 74% in 2025. The drug, which is currently approved to treat major depressive disorder (MDD) in adults, accounts for nearly 80% of the company's total revenue. Other contributions to the company's portfolio include Sunosi for narcolepsy and Symbravo for migraine relief. The Alzheimer's agitation market is vast, with over 5 million Americans estimated to suffer from the condition. Axsome's entry is particularly disruptive because Auvelity is the first approved treatment for this indication that is not an antipsychotic. Unlike the existing competitor Rexulti, Auvelity does not carry a black box warning regarding increased risk of death in elderly patients with dementia-related psychosis. Financial analysts have responded positively to the regulatory win. Both Needham & Company and TD Cowen have raised their price targets to $255 per share, reflecting the potential for the new application to generate between $1 billion and $2 billion in revenue. Axsome intends to launch the drug for this new indication within approximately one month, utilizing its existing sales infrastructure. Market participants are now focusing on the company's first-quarter earnings report, scheduled for release on Monday, May 4, for further guidance on the commercial rollout.